Short answer
EyePoint, Inc. (EYPT) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $756,000 (down 21.7% year over year) with net income of −$96M.
Q3 2026 key financials · XBRL
- Revenue
- $756,000
- −21.7% YoY · +49.1% QoQ
- Net income
- −$96M
- −60.1% YoY · −1.2% QoQ
- Operating margin
- -12814.4%
- EPS (diluted)
- −$1.07
- −25.9% YoY · +1.8% QoQ
Source: XBRL data from the EyePoint, Inc. (EYPT) Q3 2026 10-Q on SEC EDGAR. USD.
EyePoint, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue down 22% YoY, $0.7M versus $0.9M
- Net loss $95.6M versus $59.7M; R&D $81.7M, up 71% YoY
- DURAVYU R&D $55.3M versus $29.6M, strongest spending increase
- Nine-month operating cash outflow $229.7M versus $175.1M; capital expenditures $3.4M
- Cash, equivalents and investments $118.2M; runway into late Q3 2027 after $10.1M ATM proceeds
Risk Factors
- Going-concern risk: September 30 cash, equivalents and short-term investments insufficient for 12 months without additional funding
- Strategic prioritization risk: October 19 plan ends pivotal wet AMD trials early and reduces workforce approximately 53%
- Operational risk: workforce reduction may cause loss of expertise and delays to DURAVYU DME development
- Nasdaq compliance risk: $0.4041 closing price on November 10 versus $1.00 minimum bid requirement
- Market risk: shares declined significantly after LUGANO and LUCIA trial results announced in August and October 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other EyePoint, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.